Skip to main content

Advertisement

Table 3 Dose fractionation schedules of randomized trials of WBRT alone

From: Neuropsychological testing and biomarkers in the management of brain metastases

Study (ref) Year n (Gy)/number of fractions Median Survival (months)
Harwood et al [14] 1977 101 30/10 vs 10/1 4.0–4.3
Kurtz et al [15] 1981 255 30/10 vs 50/20 3.9–4.2
Borgelt et al [4] 1980 138 10/1 vs 30/10 vs 40/20 4.2–4.8
Borgelt et al [16] 1981 64 12/2 vs 20/5 2.8–3.0
Chatani et al [17] 1986 70 30/10 vs 50/20 3.0–4.0
Haie-Meder et al [18] 1993 216 18/3 vs 36/6 or 43/13 4.2–5.3
Chatani et al [19] 1994 72 30/10 vs 50/20 or 20/5 2.4–4.3
Murray et al [20] 1997 445 54.4/34 vs 30/10 4.5
  1. Survival differences between treatment arms were not significantly different in any study. Adapted from Shaw et al. [30]
  2. Reprinted with permission from the American Society of Clinical Oncology.